Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gary L Davis

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
Transplant International : Official Journal of the European Society for Organ Transplantation|May 31, 2012
Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determinedJacqueline G O'Leary, Michael A Neri, James F Trotter, et al.
The American Journal of Gastroenterology|November 26, 2003
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis CJohn B Wong, Gary L Davis, John G McHutchison, et al.
Hepatology (Baltimore, Md.)|August 27, 2003
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CGary L Davis, John B Wong, John G McHutchison, et al.
Clinical Transplantation|July 25, 2007
Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimensRobert D Anderson, Srinath Chinnakotla, Linsheng Guo, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 3, 2012
Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantationJohn K O'Connor, James Trotter, Gary L Davis, et al.
Analytical Biochemistry|March 26, 2003
A microplate assay specific for the enzyme aggrecanaseJeffery A Miller, Rui-Qin Liu, Gary L Davis, et al.
Journal of the American College of Cardiology|February 11, 2003
High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipientsRandy W Braith, Roger M Mills, Christopher S Wilcox, et al.
Hepatology (Baltimore, Md.)|July 31, 2008
Future trends in hepatology: challenges and opportunitiesVinod K Rustgi, Gary L Davis, Steven K Herrine, et al.
Proceedings (Baylor University. Medical Center)|July 9, 2011
Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantationJacqueline G O'Leary, James F Trotter, Michael A Neri, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 26, 2009
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantationSrinath Chinnakotla, Gary L Davis, Sugam Vasani, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
Transplant International : Official Journal of the European Society for Organ Transplantation|May 31, 2012
Utilization of hepatitis C antibody-positive livers: genotype dominance is virally determinedJacqueline G O'Leary, Michael A Neri, James F Trotter, et al.
The American Journal of Gastroenterology|November 26, 2003
Economic and clinical effects of evaluating rapid viral response to peginterferon alfa-2b plus ribavirin for the initial treatment of chronic hepatitis CJohn B Wong, Gary L Davis, John G McHutchison, et al.
Hepatology (Baltimore, Md.)|August 27, 2003
Early virologic response to treatment with peginterferon alfa-2b plus ribavirin in patients with chronic hepatitis CGary L Davis, John B Wong, John G McHutchison, et al.
Clinical Transplantation|July 25, 2007
Intramuscular hepatitis B immunoglobulin (HBIG) and nucleosides for prevention of recurrent hepatitis B following liver transplantation: comparison with other HBIG regimensRobert D Anderson, Srinath Chinnakotla, Linsheng Guo, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|April 3, 2012
Long-term outcomes of stereotactic body radiation therapy in the treatment of hepatocellular cancer as a bridge to transplantationJohn K O'Connor, James Trotter, Gary L Davis, et al.
Analytical Biochemistry|March 26, 2003
A microplate assay specific for the enzyme aggrecanaseJeffery A Miller, Rui-Qin Liu, Gary L Davis, et al.
Journal of the American College of Cardiology|February 11, 2003
High-dose angiotensin-converting enzyme inhibition restores body fluid homeostasis in heart-transplant recipientsRandy W Braith, Roger M Mills, Christopher S Wilcox, et al.
Hepatology (Baltimore, Md.)|July 31, 2008
Future trends in hepatology: challenges and opportunitiesVinod K Rustgi, Gary L Davis, Steven K Herrine, et al.
Proceedings (Baylor University. Medical Center)|July 9, 2011
Effect of tacrolimus on survival in hepatitis C-infected patients after liver transplantationJacqueline G O'Leary, James F Trotter, Michael A Neri, et al.
Liver Transplantation : Official Publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society|November 26, 2009
Impact of sirolimus on the recurrence of hepatocellular carcinoma after liver transplantationSrinath Chinnakotla, Gary L Davis, Sugam Vasani, et al.
Pageof 7